Related Experiment Videos
Cystic fibrosis screening in newborns: results from existing programs
S S Young1, M Kharrazi, M Pearl
1Sequoia Foundation, La Jolla, California, USA.
Insights
Newborn screening for cystic fibrosis (CF) offers early detection and treatment for infants, with consistent evidence showing significant health benefits and no harm. This approach is crucial for managing this genetic disorder.
Area of Science:
- Medical Genetics
- Pediatric Medicine
- Public Health Policy
Background:
- Cystic Fibrosis (CF) is a fatal genetic disease often misdiagnosed in infants.
- Newborn screening (NBS) aims for early identification and treatment.
- NBS for CF remains a debated topic in genetic policy.
Purpose of the Study:
- To summarize the literature on the health benefits, risks, cost-effectiveness, and programmatic issues of NBS for CF.
- To evaluate the evidence supporting NBS for CF from May 2000 to April 2001.
Main Methods:
- Literature review of studies published between May 2000 and April 2001.
- Synthesis of findings on health outcomes, risks, economic impact, and implementation challenges.
Main Results:
- Consistent evidence demonstrates health benefits associated with NBS for CF.
- The literature indicates a lack of harm resulting from NBS for CF.
- Established screening programs in Wisconsin, France, and Australia report mounting health benefits.
Conclusions:
- NBS for CF is supported by consistent evidence of benefits and absence of harm.
- The findings support the expansion and continued debate on NBS for CF implementation.
- Early detection through NBS is vital for improving outcomes in infants with cystic fibrosis.
Abstract:
Newborn screening for cystic fibrosis (CF) provides early identification and initiation of treatment to infants with this fatal and often misdiagnosed genetic disease. Although reports of health benefits continue to mount from decade-old screening programs in Wisconsin, France, and Australia, newborn screening for CF is still a highly debated topic in genetic policy development. This article summarizes the literature published between May 2000 and April 2001 regarding the health benefits, risks, cost-effectiveness, and programmatic issues of newborn screening for CF. The literature consistently shows evidence of benefits and lack of harm from newborn screening for CF.